249 related articles for article (PubMed ID: 22670584)
1. The role of irbesartan in the treatment of patients with hypertension: a comprehensive and practical review.
Borghi C; Cicero AF
High Blood Press Cardiovasc Prev; 2012 Mar; 19(1):19-31. PubMed ID: 22670584
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan.
Gialama F; Maniadakis N
Vasc Health Risk Manag; 2013; 9():575-92. PubMed ID: 24124375
[TBL] [Abstract][Full Text] [Related]
3. Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension.
Bramlage P
Vasc Health Risk Manag; 2009; 5(1):213-24. PubMed ID: 19436667
[TBL] [Abstract][Full Text] [Related]
4. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of irbesartan for hypertension.
Borghi C; Urso R; Cicero AF
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):199-207. PubMed ID: 25703678
[TBL] [Abstract][Full Text] [Related]
6. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
Mengden T; Uen S; Bramlage P
Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
Ariyoshi Y; Mizumoto K
Nihon Yakurigaku Zasshi; 2009 May; 133(5):275-80. PubMed ID: 19443965
[No Abstract] [Full Text] [Related]
8. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice.
Schmieder RE; Schwertfeger M; Bramlage P
Vasc Health Risk Manag; 2009; 5():991-1000. PubMed ID: 19997579
[TBL] [Abstract][Full Text] [Related]
9. Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan.
Bramlage P; Schindler C
Expert Opin Pharmacother; 2010 Mar; 11(4):521-35. PubMed ID: 20030566
[TBL] [Abstract][Full Text] [Related]
10. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
[TBL] [Abstract][Full Text] [Related]
11. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
12. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
13. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan and hydrochlorothiazide association in the treatment of hypertension.
Derosa G; Ferrari I; Cicero AF
Curr Vasc Pharmacol; 2009 Apr; 7(2):120-36. PubMed ID: 19355995
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
[TBL] [Abstract][Full Text] [Related]
16. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Frei A; Palmer AJ; Burnier M; Hess B
Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
[TBL] [Abstract][Full Text] [Related]
18. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study.
Mörtsell D; Malmqvist K; Held C; Kahan T
J Intern Med; 2007 May; 261(5):472-9. PubMed ID: 17444886
[TBL] [Abstract][Full Text] [Related]
19. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
20. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Neutel JM; Germino FW; Smith D
J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):84-9. PubMed ID: 16470487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
